Levi & Korsinsky Alerts Investors About Iovance Biotherapeutics Class Action Notice

Notice of Class Action Lawsuit Against Iovance Biotherapeutics Inc.

Levi & Korsinsky, LLP, a leading law firm, has reached out to investors of Iovance Biotherapeutics, Inc. (ticker: IOVA), notifying them about a class action lawsuit linked to alleged securities fraud affecting shareholders from May 9, 2024, to May 8, 2025. This notice is particularly crucial for investors who suffered financial losses during this specified period.

Overview of the Case

The lawsuit is centered on claims that Iovance misled its investors regarding its business operations, specifically concerning its growth potential. Throughout the class period, the defendants allegedly provided excessively positive statements while omitting crucial facts that could negatively impact investors' perception and decisions. The complaint points out that the company was not adequately equipped to meet actual demand for its treatments, despite its reassuring statements.

On July 25, 2024, Iovance faced a significant hit to its credibility when it announced its second-quarter financial results for FY 2024. In a concerning turn of events, the company was forced to lower its revenue guidance for the entire fiscal year. The reasons cited for this downturn included scheduled maintenance, unexpected lower Proleukin sales, and a gradual pace at which approved treatment centers began treating patients. As a result, dramatic stock price fluctuations ensued, dropping from $3.17 on May 8, 2025, to $1.75 the following day, representing a staggering 44.8% decrease in value.

Implications for Investors

For those who experienced losses related to Iovance during this timeframe, it is crucial to act before the court's deadline on July 14, 2025, to be considered for lead plaintiff status. However, it’s important to note that participating in the lawsuit does not require one to take on this role to be eligible for recovery.

No Costs Involved

Investors participating as class members will not incur any out-of-pocket expenses or fees for joining this lawsuit. This opportunity to seek compensation is extended with no obligations on the part of potential claimants, ensuring a risk-free engagement for those impacted.

Why Choose Levi & Korsinsky?

With a proven track record spanning over two decades, Levi & Korsinsky has successfully advocated for shareholders, securing hundreds of millions of recoveries in complex securities litigation. The firm enjoys recognition as a top securities litigation firm in the U.S., highlighting its commitment and extensive expertise in defending investors’ rights. Their dedicated team of over 70 professionals stands ready to assist clients throughout this process.

How to Get Involved

Affected investors can find more information on how to join the class action on Levi & Korsinsky’s official website, or by directly contacting Joseph E. Levi, Esq. at (212) 363-7500 or via email. The law firm encourages all potential claimants to take timely action to maximize their chances of recovery.

For additional details or inquiries, interested parties can reach out to Levi & Korsinsky:

- Address: 33 Whitehall Street, 17th Floor, New York, NY 10004
- Email: [email protected]

Staying informed and proactive is essential for shareholders impacted by Iovance's alleged practices. As the lawsuit progresses, affected investors should keep abreast of developments to protect their investment interests.